- Predominantly squamous cell histology NSCLC.
|
-
History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
|
-
Grade \>2 peripheral neuropathy.
|
-
History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
|
-
Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
|
-
Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
|
-
Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
|
-
Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
|
-
Known active central nervous system metastases and/or carcinomatous meningitis.
|
-
Active infection requiring systemic therapy.
|
-
History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
|
-
HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
|
-
Concurrent active HBV and HCV infection.
|
-
History of allogeneic tissue/solid organ transplant.
|
-
Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
|